Strategic Financial Concepts LLC Purchases Shares of 46,655 TG Therapeutics, Inc. (NASDAQ:TGTX)

Strategic Financial Concepts LLC bought a new position in TG Therapeutics, Inc. (NASDAQ:TGTX) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 46,655 shares of the biopharmaceutical company’s stock, valued at approximately $1,404,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in TGTX. NBC Securities Inc. grew its stake in shares of TG Therapeutics by 58.9% in the 3rd quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 485 shares during the last quarter. Blue Trust Inc. increased its holdings in shares of TG Therapeutics by 127.3% in the 3rd quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 849 shares in the last quarter. ORG Wealth Partners LLC bought a new stake in shares of TG Therapeutics in the third quarter worth $53,000. Values First Advisors Inc. bought a new stake in shares of TG Therapeutics in the third quarter worth $58,000. Finally, Synergy Asset Management LLC bought a new stake in shares of TG Therapeutics in the fourth quarter worth $75,000. Hedge funds and other institutional investors own 58.58% of the company’s stock.

Wall Street Analyst Weigh In

TGTX has been the topic of several analyst reports. StockNews.com downgraded TG Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, January 31st. JPMorgan Chase & Co. boosted their price objective on TG Therapeutics from $30.00 to $43.00 and gave the company an “overweight” rating in a research report on Monday, November 25th. TD Cowen initiated coverage on TG Therapeutics in a research report on Tuesday, October 29th. They issued a “buy” rating and a $50.00 price objective on the stock. The Goldman Sachs Group boosted their target price on TG Therapeutics from $20.00 to $22.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Finally, HC Wainwright reiterated a “buy” rating and issued a $55.00 target price on shares of TG Therapeutics in a research report on Wednesday, January 15th. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, TG Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $40.67.

TG Therapeutics Stock Down 2.5 %

TG Therapeutics stock opened at $32.25 on Tuesday. The business has a fifty day moving average of $31.38 and a two-hundred day moving average of $27.11. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27. The firm has a market cap of $5.02 billion, a P/E ratio of -322.47 and a beta of 2.26. TG Therapeutics, Inc. has a twelve month low of $12.84 and a twelve month high of $36.84.

Insider Activity

In related news, CFO Sean A. Power sold 10,021 shares of the company’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $28.53, for a total value of $285,899.13. Following the transaction, the chief financial officer now directly owns 660,611 shares of the company’s stock, valued at $18,847,231.83. This represents a 1.49 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 10.50% of the company’s stock.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.